Vonorasan tablets (i.e., vonorasan fumarate tablets) and rabeprazole both inhibit gastric acid secretion, and the efficacy of the medication varies from person to person; there is no such thing as who is more effective.
Vonorasan fumarate tablets belong to the proton pump inhibitors, used for the treatment of reflux esophagitis, contraindications include those who are allergic to the product and those who are receiving atazanavir or rilpivirine. The most common adverse reactions are diarrhea and constipation.
Rabeprazole is a common proton pump inhibitor indicated for the treatment of active gastric and duodenal ulcers, for the treatment and maintenance of erosive or ulcerative gastroesophageal reflux disease accompanied by clinical symptoms, and in combination for the eradication of Helicobacter pylori positive duodenal ulcers.
Contraindications to use include hypersensitivity to the product and benzimidazole substitutes, pregnant and lactating women. The most common adverse reactions are headache, diarrhea and nausea.
The above two drugs are proton pump inhibitors, for reflux esophagitis and other conditions have a certain therapeutic effect, but both drugs have their own preference for the population, can not be clearly stated who has better efficacy, and the specific effect of the drug also varies from person to person. The use of specific drugs should be carried out under the guidance of specialized physicians, not to use drugs at will.